Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.CRTX · Entity 7403 | EVP, Preclinical Development | June 06, 2022 | June 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date June 06, 2022 · Filed June 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 148,080 |
Reported balance
After 2022-06-06 transaction · row 1
1 source rowRow 1 · 2022-06-06 · Tax withholding · Disposed 10,920 · Balance 148,080 F1: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 19,437 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 19,437 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2022 Filed Jun 8, 2022 20:10 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Tax withholdingCommon Stock | 10,920 | $2.86 | $31,231.20 |
DisclosureSEC source: 0001209191-22-035017 · doc4.xml · nonDerivative · entry 1 Holsinger Leslie · CIK 0001770821 · EVP, Preclinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,080 F1 · shares: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 19,437 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 22:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantCommon Stock | 155,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016429 · doc4.xml · nonDerivative · entry 1 Holsinger Leslie · CIK 0001770821 · EVP, Preclinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,000 F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:57 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock option (right to buy) · Derivative | 125,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001209191-22-001759 · doc4.xml · derivative · entry 1 Holsinger Leslie · CIK 0001770821 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · derivative · entry 10 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,794 Underlying: Common Stock · 40,000 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested at the rate of 25% of the shares on April 4, 2017, and the remaining 75% of shares vested in equal monthly installments beginning on May 4, 2017 until all the shares were fully vested on April 4, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 900 | $32.59 | $29,331.00 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · nonDerivative · entry 7 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 400 | $32.59 | $13,034.00 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · nonDerivative · entry 6 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 9,525 | $31.79 | $302,799.75 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · nonDerivative · entry 5 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 13,200 | $30.91 | $408,012.00 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · nonDerivative · entry 4 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,325 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 14,275 | $30.15 | $430,391.25 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · nonDerivative · entry 3 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,525 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 1,700 | $28.80 | $48,960.00 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · nonDerivative · entry 2 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 40,000 | $0.27 | $10,800.00 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · nonDerivative · entry 1 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · derivative · entry 9 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-10 F3 · derivative.exercise_date: 50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share. Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 00:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-063615 · doc4.xml · derivative · entry 8 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-10 F2 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 22:16 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001209191-20-063277 · doc4.xml · derivative · entry 2 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,794 Underlying: Common Stock · 3,500 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested at the rate of 25% of the shares on April 4, 2017, and the remaining 75% of shares vested in equal monthly installments beginning on May 4, 2017 until all the shares were fully vested on April 4, 2020. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 22:16 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 3,500 | $0.27 | $945.00 |
DisclosureSEC source: 0001209191-20-063277 · doc4.xml · nonDerivative · entry 1 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 18:14 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $45.88 | $0.00 |
DisclosureSEC source: 0001209191-20-030022 · doc4.xml · derivative · entry 1 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to this option will vest and become exercisable on each monthly anniversary of the vesting start date, beginning March 29, 2020. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 23:11 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $54.85 | $0.00 |
DisclosureSEC source: 0001209191-20-008066 · doc4.xml · derivative · entry 1 Holsinger Leslie · CIK 0001770821 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest and become exercisable monthly over four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.